Mehdi Chelbi

@BowTiedBiotech Indeed this is the solution and it exist for real ! Check G.CLIPS enabling technology gclips-biotech.com we are able to produce stabilized membrane proteins in the desired conformation and to perform the pharmacological profiling of NCEs mAbs and CARs 😉

😌PROBLEM: Membrane proteins such as GPCRs are challenging to drug bc we cannot stabilize the proteins/domains to screen drug libraries against. (i.e., it’s a protein production problem) 🤖SOLUTION: Computational design of soluble and functional membrane protein analogues If you can make the proteins and they are stable not bound to membrane, then you can screen drug libraries against them - see below for SEC-MALS porn 😮 “Specifically in GPCR drug development, it would be transformative to create soluble analogues in specific functional states that could be used for small-molecule or antibody discovery campaigns.” nature.com/articles/s4158… 🇨🇭

BiPER Therapeutics is committed to the fight against cancer / BiPER Therapeutics est engage dans la luttte contre le cancer Let s fight together ! #WorldCancerDay #CloseTheCareGap

What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicine on the PANDA trial: neoadjuvant atezo+chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 nature.com/articles/s4159…

GI cancers are the main cause of cancer-related deaths worldwide including 1/3 of deaths related to cancers. Yet research is underfunded and hospital staff is underrepresented.

GRP78 is a promising new pan-cancer target for CAR-T therapy (but with a twist). Great preclinical study by @Jorge88382322 @GiedreKrenciute @PaulinaV_MD and the St Jude team cell.com/cell-reports-m…

@MaxMamonkin @Jorge88382322 @GiedreKrenciute @PaulinaV_MD Great work confirming GRP78 as a relevant target to treat cancers

@tariqkrim @Xavier75 @Xavier75 il y a des choses a faire sur les 3 volets. Pret a y contribuer et partager mon retour d experience.

comme toujours, très bon discours de @Xavier75 #Big2023 youtu.be/Mnc2TeNuSo0?si…

Our SnapShot on Cancer Chemotherapy has just been published in @CellCellPress bit.ly/3og6XSc #Cancer #Chemotherapy #CancerResearch

🔥Just out: The ESMO #GastricCancer Living Guideline 👉get the latest news & updates for daily decision making @myESMO @OncoAlert

'BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist' shorturl.at/hyR04 My husband and I share our views on #BRAFV600E #CRC as a #patient and a #caregiver with the expert Christelle de la Fouchardière

Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins | Nature Chemical Biology nature.com/articles/s4158…

@AssurancesBPCE Merci. J attends donc que cela avance concretement et rapidement. Bien a vous

@Mehdical Bonjour monsieur, nous vous avons répondu en message privé. Cordialement

@AssurancesBPCE est ce que vous comptez repondre un jour ?? 6 mois depuis mon degat des eaux et AUCUNE reponse ni par mail ni par telephone 😡😡😡 !!!!

New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer bit.ly/3quY1JZ @VanMorrisMD @mdmanishshah @DrRonanKelly

At @ASCO, @BeiGeneGlobal presented positive results from their phase 3 study of tislelizumab plus chemotherapy as a first-line treatment of advanced gastric cancer that demonstrated meaningful improvement in overall survival. businesswire.com/news/home/2023…

@jsoriamd Thanks Dr @jsoriamd we are targeting an explored one @ BiPER Therapeutics and hope to make our asset enter into the clinic very soon 😉

An analysis of biopharma #pipelines shows that the average number of assets per target investigated has more than doubled: 3 assets/target in 2000 to 7 today. The number of assets in clinical development is outpacing the number of biological approaches, particularly in oncology. nature.com/articles/d4157…

✳️A nice article showing tumor mutation burden alone relatively irrelevant for IO response among MSS GI cancers particularly for MSS CRC❗️ Why?👇 @OncoAlert @TheColonClub @TheColonClub @manjuggm @UPMCHillmanCC thelancet.com/journals/lanon…

Amazing day! #gpcr #drgpcr

BiPER Therapeutics fait partie de le selection @Challenges des 100 start ups ou #investir. Notre candidat medicament a une approche unique pour traiter les patients atteints de #Cancers gastrointestinaux www-challenges-fr.cdn.ampproject.org/c/s/www.challe…

Nature research paper: Autoregulation of GPCR signalling through the third intracellular loop go.nature.com/3FbqgSF